New Pharmaceuticals market report from Global Markets Direct: "Transplantation - Pipeline Review, H2 2013"
Boston, MA -- (SBWIRE) -- 09/24/2013 -- Global Markets Direct's, 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
View Full Report Details and Table of Contents
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Transplantation.
- A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Transplantation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to Get This Report
- Identify and understand important and diverse types of therapeutics under development for Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Transplantation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Hospira, Inc., F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Osiris Therapeutics, Inc., Athersys, Inc., GlaxoSmithKline plc, Quark Pharmaceuticals, Inc., Merck & Co., Inc., AbGenomics International, Inc., Emergent BioSolutions Inc., Oxford BioMedica plc, Pharming Group N.V., Vectura Group plc, BioLineRx, Ltd., Novartis AG, Isotechnika Pharma Inc., Samyang Corporation, Astellas Pharma Inc., ViroPharma Incorporated, Cell Therapeutics, Inc., Genmab A/S, Exelixis, Inc., 4SC AG, Celldex Therapeutics, Inc., IMMUNOMEDICS, INC, Antisense Therapeutics Limited, LifeCycle Pharma A/S, Mesoblast Ltd, Biovitrum AB, NPS Pharmaceuticals, Inc., Circadian Technologies Limited, Cleveland BioLabs, Inc., Accentia Biopharmaceuticals, Inc., La Jolla Pharmaceutical Company, Jazz Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc., Cerimon Pharmaceuticals, Inc., Soligenix, Inc., NeoStem, Inc., JCR Pharmaceuticals Co., Ltd., Pluristem Therapeutics Inc., Synta Pharmaceuticals Corp., MediPost Co., Ltd., Hansa Medical AB, Proteo, Inc., Cellerant Therapeutics, Inc., Digna Biotech, S.L., Spectrum Pharmaceuticals, Inc., Viron Therapeutics, Inc., Palau Pharma S.A, Actinium Pharmaceuticals, Inc., Pharmagenesis, Inc., Pharmalink AB, Wellstat Therapeutics Corporation, Argos Therapeutics, Inc., APT Pharmaceuticals, Inc., Alder Biopharmaceuticals Inc., Gene Signal International SA., ApoImmune, Inc., Recoly N.V., Opsona Therapeutics Ltd., TetraLogic Pharmaceuticals, Conatus Pharmaceuticals Inc., MSM Protein Technologies, Inc., Angion Biomedica Corp., NovImmune SA, TcL Pharma SAS, Polyphor Ltd., Omeros Corporation, iBio, Inc., Kiadis Pharma B.V., CG Therapeutics, Inc., Bellicum Pharmaceuticals, Inc., Sirnaomics, Inc., USV Limited., Limerick BioPharma, Inc., KYORIN Pharmaceutical Co., Ltd., Tolera Therapeutics, Inc., TaiGen Biotechnology Co., Ltd., Medistem, Inc., KAHR medical Ltd., Medestea Research & Production S.p.A., NasVax Ltd., Ikaria Inc., REGiMMUNE Corporation, ADIENNE Pharma & Biotech, TikoMed AB, Nephrx Corporation, Dr. Falk Pharma GmbH, Dompe Farmaceutici S.p.A., AIMM Therapeutics B.V., Amplimmune, Inc., Lycera Corp., Bio Sidus S.A., Icon Bioscience, Inc., Therapure Biopharma Inc., FCB-Pharmicell Co.,Ltd., iTherX Pharmaceuticals Inc., ToleroTech Inc., CellAct Pharma GmbH, Sigmoid Pharma., America Stem Cell, Inc.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013
- Liver Transplantation - Pipeline Review, H2 2013
- Bone Marrow Transplantation - Pipeline Review, H2 2013
- Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013
- Crohn's Disease - Pipeline Review, H2 2013
- Myelodysplastic Syndrome - Pipeline Review, H2 2013
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
- Huntington's Disease - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013
- Influenza - Pipeline Review, H2 2013